Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Watson recalls fentanyl patches in US

This article was originally published in Scrip

Executive Summary

Watson Pharmaceuticalsis recalling one lot of fentanyl transdermal system patches in the US because of the potential for leakage. The 75μg/hr patches were shipped between January 30th and March 19th. Patches leaking fentanyl gel have been detected, potentially directly exposing patients and caregivers to the active ingredient. No injuries have been reported, but exposure to fentanyl gel may lead to respiratory depression, overdose and death. Leaks have proved to be a problem for several companies marketing fentanyl patches. Earlier this year Actavis recalled all fentanyl patches sold in the US owing to a possible fold-over defect that could cause leakage. Johnson & Johnson recalled all lots of 25μg/hour Duragesic patches and 25μg/hour fentanyl patches sold by Novartis's Sandoz unit because the products may have a cut along one side, which could result in leakage. Recalls also were initiated by J&J and Ranbaxy Laboratories in Canada.

You may also be interested in...



Biosimilars: US FDA Considering ‘Guardrails’ To Prevent Misinformation

Agency wants to ensure patients ‘aren’t unnecessarily or unfairly scared off or intimidated’ from taking biosimilars, Office of Therapeutic Biologics and Biosimilars' acting policy director Eva Temkin tells the FDA/CMS Summit; Temkin says recent guidance on biosimilar insulins shows agency is trying to be flexible on interchangeability data requirements.


Lynparza, Keytruda Supplemental Indications Face US FDA Panel Review

AstraZeneca and Merck seek to add a pancreatic cancer indication for olaparib, while Merck has hopes of broadening pembrolizumab’s use in bladder cancer; two-day Oncologic Drugs Advisory Committee meeting also will include reviews of Celgene’s luspatercept in myelodysplastic syndromes-related anemia and Epizyme’s tazemetostat for epithelioid sarcoma.

Antibiotics: Leveraging Off-Label Efficacy Data Needed To Drive Appropriate Use, Reimbursement

Clinicians and sponsors want the US FDA to open up antibacterial labeling to include more data on efficacy against resistant pathogens and in other body sites, but regulatory restrictions may require a workaround in the form of rapid, peer-to-peer communications about the data on new products.

Topics

Related Companies

UsernamePublicRestriction

Register

SC031258

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel